Literature DB >> 31927171

Fast MRI breast cancer screening - Ready for prime time.

Sasan Partovi1, David Sin2, Ziang Lu3, Leah Sieck3, Holly Marshall3, Ramya Pham3, Donna Plecha3.   

Abstract

OBJECTIVE: The manuscript discusses landmark studies using abbreviated MRI for breast cancer screening. This includes abbreviated dynamic contrast enhanced MRI and diffusion weighted imaging. Our institutional experience with abbreviated MR protocol for breast cancer screening is also described.
CONCLUSION: Abbreviated MRI protocols were found to demonstrate value for screening of breast cancer. It has been shown that abbreviated protocol MRI provides similar diagnostic sensitivities to full protocol MRI for breast cancer in women with increased lifetime risk. Our institutional abbreviated MRI protocol for breast cancer offers improved time and workflow efficiencies and has the potential to increase the number of breast cancers detected and the detection of pathologically relevant invasive breast cancer at earlier stages.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Abbreviated protocol; Breast Cancer screening; Breast imaging; Magnetic resonance imaging

Year:  2019        PMID: 31927171     DOI: 10.1016/j.clinimag.2019.10.013

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  13 in total

1.  Breast cancer screening programs: does one risk fit all?

Authors:  Federica Pediconi; Francesca Galati
Journal:  Quant Imaging Med Surg       Date:  2020-04

2.  Using deep learning to safely exclude lesions with only ultrafast breast MRI to shorten acquisition and reading time.

Authors:  Xueping Jing; Mirjam Wielema; Ludo J Cornelissen; Margo van Gent; Willie M Iwema; Sunyi Zheng; Paul E Sijens; Matthijs Oudkerk; Monique D Dorrius; Peter M A van Ooijen
Journal:  Eur Radiol       Date:  2022-05-26       Impact factor: 5.315

3.  Outcomes of Abbreviated MRI (Ab-MRI) for Women of any Breast Cancer Risk and Breast Density in a Community Academic Setting.

Authors:  Kaitlyn Kennard; Olivia Wang; Stephanie Kjelstrom; Sharon Larson; Lina M Sizer; Catherine Carruthers; William B Carter; Robin Ciocca; Jennifer Sabol; Thomas G Frazier; Ned Z Carp
Journal:  Ann Surg Oncol       Date:  2022-07-20       Impact factor: 4.339

4.  Management of Non-Mass Enhancement at Breast Magnetic Resonance in Screening Settings Referred for Magnetic Resonance-Guided Biopsy.

Authors:  Eduardo de Faria Castro Fleury; Caio Castro; Mario Sergio Campos do Amaral; Décio Roveda Junior
Journal:  Breast Cancer (Auckl)       Date:  2022-05-16

5.  Breast Tumor Identification in Ultrafast MRI Using Temporal and Spatial Information.

Authors:  Xueping Jing; Monique D Dorrius; Mirjam Wielema; Paul E Sijens; Matthijs Oudkerk; Peter van Ooijen
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

Review 6.  A Concise Review on the Utilization of Abbreviated Protocol Breast MRI over Full Diagnostic Protocol in Breast Cancer Detection.

Authors:  Haytham Al Ewaidat; Mohammad Ayasrah
Journal:  Int J Biomed Imaging       Date:  2022-04-28

7.  Combined molybdenum target X-ray and magnetic resonance imaging examinations improve breast cancer diagnostic efficacy.

Authors:  Wen-Quan Gu; Sun-Mei Cai; Wei-Dong Liu; Qi Zhang; Ying Shi; Li-Juan Du
Journal:  World J Clin Cases       Date:  2022-01-14       Impact factor: 1.337

8.  Correlation between Imaging Features and Pathological Stages of Primary Lung Tumors Based on Nanocontrast Agents.

Authors:  Jin Li; Qian Xu; Cunhua Mao; Yuliang Liu
Journal:  Comput Math Methods Med       Date:  2021-11-08       Impact factor: 2.238

9.  Current and Future Directions of Breast MRI.

Authors:  Margaret Houser; David Barreto; Anita Mehta; Rachel F Brem
Journal:  J Clin Med       Date:  2021-11-30       Impact factor: 4.241

10.  Diagnostic performance of dynamic contrast-enhanced magnetic resonance imaging for breast cancer detection: An update meta-analysis.

Authors:  Honghuan Dong; Linqing Kang; Sijia Cheng; Rongju Zhang
Journal:  Thorac Cancer       Date:  2021-10-20       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.